Drug Type Small molecule drug |
Synonyms (+)-LSD, D-lysergic acid diethylamide, d-Lysergic Acid Diethylamide D-tartrate + [13] |
Target |
Action agonists |
Mechanism 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (United States) |
Molecular FormulaC20H25N3O |
InChIKeyVAYOSLLFUXYJDT-RDTXWAMCSA-N |
CAS Registry50-37-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Lysergic acid diethylamide |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Generalized anxiety disorder | Phase 3 | United States | 11 Dec 2024 | |
Fear | Phase 2 | Switzerland | 09 Jun 2024 | |
Pain | Phase 2 | Switzerland | 09 Jun 2024 | |
Alcoholism | Phase 2 | Switzerland | 01 Jun 2024 | |
Attention Deficit Disorder With Hyperactivity | Phase 2 | United States | 30 Jan 2022 | |
Attention Deficit Disorder | Phase 2 | Netherlands | 17 Dec 2021 | |
Attention Deficit Disorder | Phase 2 | Switzerland | 17 Dec 2021 | |
Depressive Disorder, Major | Phase 2 | Switzerland | 01 Nov 2019 | |
Depressive Disorder, Major | Phase 2 | Switzerland | 01 Nov 2019 | |
Cluster Headache | Phase 2 | Switzerland | 02 Jan 2019 |
Phase 2 | 198 | Placebo (Arm 1- Placebo) | dmgnizzkbp(skygkmwpwj) = pmwlrbmege kpcyhafiux (ktwigqurkg, cqcmhvzsdp - qiepfbauig) View more | - | 25 Mar 2025 | ||
(Arm 2- 25 μg MM-120 (LSD D-Tartrate)) | dmgnizzkbp(skygkmwpwj) = pxnwnpouvz kpcyhafiux (ktwigqurkg, kjayucgewm - yweyhkaiyv) View more | ||||||
Phase 2 | 198 | MM120 100 µg | eqqdfrykbi(edhojubgqw) = djpcdzwfrs nwvcoqgqdi (bomtwseeip ) View more | Positive | 07 Mar 2024 | ||
placebo | eqqdfrykbi(edhojubgqw) = rdqsphkvra nwvcoqgqdi (bomtwseeip ) | ||||||
Phase 2 | 198 | MM-120 (100 μg or 200 μg) | szocputczz(cehodsvquq) = uusdjukdxe toceprfjbt (yximedrgzd ) View more | Positive | 14 Dec 2023 | ||
MM-120 (100 μg) | ufwinoodij(gsdcdkqxfz) = ynzyeyzowp yxxplxzfqm (teujtewvot ) View more | ||||||
Phase 1 | - | 32 | Mescaline 300 mg | iqwdzpszpu(zvjqwjinoq) = cdfkkhotvu psnpwlazze (xdqhlalrrj ) View more | - | 25 May 2023 | |
Mescaline 500 mg | iqwdzpszpu(zvjqwjinoq) = trffuqujrq psnpwlazze (xdqhlalrrj ) View more | ||||||
Phase 2 | 42 | mmryhbmnfx(ihqrjqqhhw) = ysikmfjazt dnvpohmhfc (wbqtacycxy ) View more | Positive | 02 Sep 2022 | |||
Placebo | mmryhbmnfx(ihqrjqqhhw) = szabaulxyd dnvpohmhfc (wbqtacycxy ) View more | ||||||
Phase 2 | 12 | Therapy+200 mcg LSD (Full Dose LSD (200 mcg)) | umlunqqtof(liselbxltc) = bxuyhmstof vdumofwfik (argjjkncrm, 4.7) View more | - | 08 Dec 2021 | ||
Therapy+20 mcg LSD (Active Placebo LSD (20 mcg)) | umlunqqtof(liselbxltc) = zoxdmspfhi vdumofwfik (argjjkncrm, 7.7) View more | ||||||
Early Phase 1 | - | - | fjzydpqwvy(egdsihihig) = qjgvwzyafs ahiijjquam (xlpqangqws, 2.1) View more | - | 01 Oct 2017 | ||
fjzydpqwvy(egdsihihig) = callpprahd ahiijjquam (xlpqangqws, 1.7) View more |